{"id":994,"date":"2019-12-20T11:42:47","date_gmt":"2019-12-20T10:42:47","guid":{"rendered":"https:\/\/dose-innova.ccoo.cat\/?p=994"},"modified":"2019-12-20T11:42:47","modified_gmt":"2019-12-20T10:42:47","slug":"sol%c2%b7licitud-de-mediacio-al-tlc-ii","status":"publish","type":"post","link":"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/sol%c2%b7licitud-de-mediacio-al-tlc-ii\/","title":{"rendered":"Sol\u00b7licitud de mediaci\u00f3 al TLC (II)"},"content":{"rendered":"<p><span style=\"font-weight: 400\">Ahir dia 19 de desembre, en les instal\u00b7lacions del Tribunal Laboral de Catalunya, es va celebrar reuni\u00f3 conjunta entre el Comit\u00e8, l&#8217;Empresa i els membres de la Comissi\u00f3 de Mediaci\u00f3 del Tribunal.<\/span><\/p>\n<p><span style=\"font-weight: 400\">En aquesta reuni\u00f3 Comit\u00e8 i Empresa van plantejar els diferents posicionaments i argumentacions respecte als temes objecte de l&#8217;expedient presentat:<\/span><\/p>\n<ol>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">La supressi\u00f3 del pagament dels km en hores extres.<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">La supressi\u00f3 de la jornada de 4 hores de l&#8217;\u00faltim dia laboral de l&#8217;any.<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">El minvament en la quantia econ\u00f2mica del lot en 2018.<\/span><\/li>\n<\/ol>\n<p><span style=\"font-weight: 400\">Una vegada constatada la impossibilitat d&#8217;aconseguir un acord entre les dues parts, i en atenci\u00f3 a les argumentacions de totes dues representacions, la Comissi\u00f3 de Mediaci\u00f3 va proposar com a via de soluci\u00f3 al conflicte plantejat, sotmetre la discrep\u00e0ncia existent a un procediment arbitral de dret, que haur\u00e0 de ser dirimit per un \u00e0rbitre del Cos Laboral d&#8217;\u00c0rbitres del propi Tribunal Laboral de Catalunya.<\/span><\/p>\n<p><span style=\"font-weight: 400\">En cas que les dues parts acceptin sotmetre la discrep\u00e0ncia a arbitratge, el present Acte de Mediaci\u00f3 finalitzar\u00e0 amb ACORD i per tant, es procedir\u00e0 a citar novament a les parts per a la confecci\u00f3 del preceptiu conveni arbitral. El Comit\u00e8 ha comunicat avui al <\/span><span style=\"font-weight: 400\">TLC <\/span><span style=\"font-weight: 400\">que accepta la proposta d&#8217;arbitratge del Tribunal.<\/span><\/p>\n<p><span style=\"font-weight: 400\">L&#8217;empresa ha de respondre amb data l\u00edmit de 23 de desembre. De no acceptar la proposta d&#8217;arbitratge, la Comissi\u00f3 de Mediaci\u00f3 procedir\u00e0 a tancar les actuacions del present expedient amb el resultat de SENSE ACORD.<\/span><\/p>\n<p>&nbsp;<\/p>\n<p><span style=\"font-weight: 400\">Martorelles, 20 de desembre de 2019.<\/span>    \t<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Ahir dia 19 de desembre, en les instal\u00b7lacions del Tribunal Laboral de Catalunya, es va celebrar reuni\u00f3 conjunta entre el Comit\u00e8, l&#8217;Empresa i els membres de la Comissi\u00f3 de Mediaci\u00f3 &#8230; <a title=\"Sol\u00b7licitud de mediaci\u00f3 al TLC (II)\" class=\"read-more\" href=\"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/sol%c2%b7licitud-de-mediacio-al-tlc-ii\/\" aria-label=\"Leer m\u00e1s sobre Sol\u00b7licitud de mediaci\u00f3 al TLC (II)\">Leer m\u00e1s<\/a><\/p>\n","protected":false},"author":59,"featured_media":694,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13,26],"tags":[],"class_list":["post-994","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-towa-pharmaceutical-europe-app-push","category-notesinformatives_ca","generate-columns","tablet-grid-50","mobile-grid-100","grid-parent","grid-33"],"_links":{"self":[{"href":"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/wp-json\/wp\/v2\/posts\/994","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/wp-json\/wp\/v2\/users\/59"}],"replies":[{"embeddable":true,"href":"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/wp-json\/wp\/v2\/comments?post=994"}],"version-history":[{"count":0,"href":"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/wp-json\/wp\/v2\/posts\/994\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/wp-json\/wp\/v2\/media\/694"}],"wp:attachment":[{"href":"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/wp-json\/wp\/v2\/media?parent=994"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/wp-json\/wp\/v2\/categories?post=994"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/wp-json\/wp\/v2\/tags?post=994"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}